Details

Autor(en) / Beteiligte

• Wesevich, Austin
• Goldstein, Daniel A.
• Paydary, Koosha
• Peer, Cody J.
• Figg, William D.
• Ratain, Mark J.

Titel

Interventional pharmacoeconomics for immune checkpoint inhibitors through alternative dosing strategies

Ist Teil von

• British journal of cancer, 2023-10, Vol.129 (9), p.1389-1396

Ort / Verlag

London: Nature Publishing Group UK

Erscheinungsjahr

2023

Quelle

MEDLINE

Beschreibungen/Notizen

• Immune checkpoint inhibitors (ICIs) are approved for the treatment of a variety of cancer types. The doses of these drugs, though approved by the Food and Drug Administration (FDA), have never been optimised, likely leading to significantly higher doses than required for optimal efficacy. Dose optimisation would hypothetically decrease the risk, severity, and duration of immune-related adverse events, as well as provide an opportunity to reduce costs through interventional pharmacoeconomic strategies such as off-label dose reductions or less frequent dosing. We summarise existing evidence for ICI dose optimisation to advocate for the role of interventional pharmacoeconomics.